Valproic acid in migraine prophylaxis of young patients. Three new reports

Acta Biomedica de l'Ateneo Parmense

Volumn 73, Issue 3-4, 2002, Pages 47-51

  Fusco, Carlo ^a   Pisani, Francesco ^a   Capone, Carlo ^a   Faienza, Carmine ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Juvenile migraine; Migraine; Pediatric age; Prophylaxis; Valproic acid

Indexed keywords

ACETYLSALICYLIC ACID; CAFFEINE; CYPROHEPTADINE; ERGOTAMINE; FLUNARIZINE; IBUPROFEN; KETOROLAC; SUMATRIPTAN; VALPROIC ACID;

ADOLESCENT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; HUMAN; LOW DRUG DOSE; MALE; MIGRAINE; PROPHYLAXIS; SCHOOL CHILD; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

ADOLESCENT; CHILD; HUMANS; MALE; MIGRAINE DISORDERS; VALPROIC ACID;

EID: 0036908046     PISSN: 03924203     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Erdemoglu AK, Ozbakir S. Valproic acid prophylaxis of refractory migraine. Acta Neurol Scand 102(6): 354-8, 2000.
2. Klapper J. Divalproex sodium in migraine prophylaxis: A dose controlled study. Cephalalgia 17: 103-108, 1997.
3. Kinze S, Clauss M, Reuter U, Wolf T, Dreier JP, Einhaupl KM, Arnold G. Valproic acid is effective in migraine prophylaxis at low serum levels: A prospective open-label study. Headache 41(8): 774-8, 2001.
4. Mathew NT, Saper JRS, Silberstein SD, Rankin L, Markley HG, Solomon S, Rapaport AM, Silber J, Deaton RL. Migraine prophylaxis with divalproex. Arch Neurol 52: 281-286, 1995.
5. Mathew NT. Antiepileptic drugs in migraine prevention. Headache; S(1): 18-24, 2001.
6. Rothrock JF. Clinical studies of valproate migraine prophylaxis. Cephalalgia 17: 81-3, 1997.
7. Rothrock JF, Mendizabal JE. An analysis of the "carry-over effect" following successful short-term treatment of transformed migraine with divalproex sodium. Headache 40: 17-19, 2000.
8. Silberstein SD, Wilmore JL. Valproex sodium: Migraine treatment and monitoring. Headache 36: 239-242, 1996.
9. Silberstein SD. Valproex sodium in headache: Literature review and clinical guidelines. Headache 36(9): 547-55, 1996.
10. Silberstein SD, Collins SD. Safety of divalproex sodium in migraine prophylaxis: An open label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 39(9): 633-43, 1999.
11. Taylor K, Goldstein J. High dose versus low-dose valproic acid as a prophylactic medication. Headache 36(8): 514-515, 1996.
12. Hering R, Kurutzky A. Sodium valproate in the prophylactic treatment of migraine: A double-blind study versus placebo. Cephalalgia 12(2): 81-84, 1992.
13. Hering R, Steiner TJ. Sodium valproate for acute migraine attacks (letter). Cephalalgia 14(4): 305-306, 1994.
14. Jensen R, Brinck T, Olesen J. Sodium valproate has a prophylactic effect in migraine without aura: A triple blind, placebo-controlled crossover study. Neurology 44(4): 647-51, 1994.
15. Mitsikostas DD, Polychronidis I. Valproate versus flunarizine in migraine prophylaxis: A randomized, double-open, clinical trial. Funct-Neurol 12(5): 267-276, 1997.
16. Kaniecki RG. A comparision of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 54: 1141-1145, 1997.
17. Rothrock JF, Kelly NM, Brody ML, Goldbeck A. A differential response to treatment with divalproex sodium in patients with intractable headache. Cephalalgia 14: 241-4, 1994.
18. Mathew NT. Valproate in intractable headache (editorial; comment). Cephalalgia 14(3): 182-188, 1994.
19. Diener HC, Kaube H, Limmroth V. Antimigraine drugs. J Neurol 246(7): 515-9, 1999.
20. Norton J. Use of intravenous valproate sodium in status migraine. Headache 40(9): 755-7, 2000.
21. Mathew NT, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (Depacon) aborts migraine rapid preliminary report. Headache 40(9): 720-3, 2000.
22. Pakalnis A, Greenberg G, Drake ME Jr, Paolochi J. Pediatric migraine prophylaxis with divalproex. J Child Neurology 16(10): 731-4, 2001.
23. Caruso JM, Brown WD, Exil G, Gascon GG. The efficacy of divalproex sodium in the prophylactic treatment of children with migraine. Headache 40(8): 672-6, 2000.
24. Headache Classification Commitee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 8(S7): 1-96, 1988.
25. Richens A. Pharmacology and pharmacokinetics of antiepiletic drugs. In: Sheila Wallace, eds. Epilepsy in Children, London 1996.
26. Loscher W. Valproate: A reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58(1): 31-59, 1999.
27. Nishikawa T, Scatton B. Inhibitory influence of GABA on central serotonergic transmission: As the neuroanatomical site of the GABAergic inhibition of cerebral serotonergic neurons. Brain Res 33: 91-103, 1985.
28. Goadsby P, Piper RD, Lambert GA, Lance JW. Effect of stimulation of nucleus raphe dorsalis on carotid blood flow. I. The monkey. Am J Physiol 248: 257-262, 1985.
29. Cutrer FM, Limmroth V, Moskowitz. Possible mechanism of valproate in migraine prophylaxis. Cephalalgia 17: 93-100, 1997.
30. Mitsikostas DD. The valproate mechanism of action in migraine. Cephalagia 14(6): 465, 1994.
31. Sorensen KV. Valproate: A new drug in migraine prophylaxis. Acta Neurologica Scandinava 78: 346-348, 1988.